Every Sunday, the Cutter family holds a Chemofeast. The door to their home is open to any and all who wish to attend. It’s a day full of food, beverages, and a lot of laughter, and 15-year-old Blake Cutter gets to choose the menu. Then on Monday, his mother, Lois, drives him to chemotherapy at Dana-Farber.
The dirt roads in northern Rwanda now lead to a cancer center where patients can receive care for a disease that was, until now, considered a death sentence there. The Butaro Cancer Center of Excellence, which was dedicated on July 18, has allowed Dana-Farber/Brigham and Women’s Cancer Center to extend a helping hand in this tiny, densely populated country in Africa.
Recent concerns about availability and authenticity of certain drugs have generated news headlines worldwide and raised anxiety levels for some cancer patients and their families. Sylvia Bartel, RPh, MHP, Dana-Farber’s vice president of Pharmacy, says that although the cause of the two problems is unrelated, it underscores the need for continuous and careful monitoring and management of the Institute’s medications.
Harold J. Burstein, MD, PhD, a Dana-Farber breast cancer specialist, discusses some of the important studies presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The five-day meeting includes more than 1,000 scientific presentations, seminars, and posters, with a focus on emerging treatments in hard-to-treat populations, patients with metastatic breast cancer, and breast cancer prevention and risk. Around 8,000 breast cancer experts from 90 countries are attending the symposium to learn about the latest developments in breast cancer care and research.